Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Delivered $450 million in full-year net sales for 2025, establishing XDEMVY as a breakout therapeutic and the company as a leader in eye care. Achieved profitability at the product line level for XDEMVY, providing financial flexibility to reinvest in high-return growth drivers. Expanded the addressable market focus beyond the initial 9 million patients to the full 25 million Americans with Demodex blepharitis as screening becomes routine. Attributed commercial success to a 'repeatable playbook' that ...